Back to results
US 2009/0275049 A1Published application
EphA4 POLYPEPTIDE HAVING A NOVEL ACTIVITY AND USE THEREOF
AssigneeEisai R&D Management Co., Ltd.
InventorsEiji Inoue, Maki Tawarada, Aki Togawa, Emiko Kamakura
Life of this patent
Estimating the term…
Abstract
The present invention provides a polynucleotide which consists of a partial sequence of a polynucleotide encoding the amino acid sequence as shown in SEQ ID NO: 2, wherein the former polynucleotide encodes a polypeptide consisting of a partial amino acid sequence of SEQ ID NO: 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO: 2.
Claims27
1:
- A polynucleotide consisting of a partial sequence of a polynucleotide encoding the amino acid sequence as shown in SEQ ID NO:
- 2, wherein the former polynucleotide encodes a polypeptide consisting of a partial amino acid sequence of SEQ ID NO:
- 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO:
- 2.
1 more element
2:
- The polynucleotide according to claim 1, wherein the polynucleotide encodes the amino acid sequence of a polypeptide having the following activity (a) or (b):
- (a) promoting spine formation;
- or
- (b) activating Rac.
1 more element
3:
- A polynucleotide consisting of a partial sequence of a polynucleotide encoding the amino acid sequence as shown in SEQ ID NO:
- 2, wherein the former polynucleotide has the following nucleotide sequence (a) or (b) and yet encodes the amino acid sequence of a polypeptide having the following activity (c) or (d):
- (a) a nucleotide sequence having at least 95% or more homology to a nucleotide sequence encoding a polypeptide consisting of a partial amino acid sequence of SEQ ID NO:
- 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO:
- 2;
- or
- (b) a nucleotide sequence which hybridizes to the complementary strand of a nucleotide sequence encoding a polypeptide consisting of a partial amino acid sequence of SEQ ID NO:
- 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO:
- 2 under stringent conditions;
- (c) promoting spine formation;
- or
- (b) activating Rac.
9 more elements
4:
- A polynucleotide selected from the following (a), (b) and (c):
- (a) a polynucleotide encoding the amino acid sequence as shown in SEQ ID NO:
- 2n where n represents an integer from 45 to 83;
- (b) a polynucleotide consisting of the nucleotide sequence as shown in SEQ ID NO:
- 2n−1 where n represents an integer from 45 to 83;
- and
- (c) a polynucleotide which hybridizes to the complementary strand of the polynucleotide (a) or (b) under stringent conditions and yet encodes a polypeptide having the following activity (d) or (e):
- (d) promoting spine formation;
- or
- (e) activating Rac.
7 more elements
5:
- A polynucleotide encoded by the nucleotide sequence as shown in SEQ ID NO:
- 89, 91 or 195.
6:
- The polynucleotide according to any one of claims 1, 3, 4 or 5, wherein the polynucleotide encodes an amino acid sequence of a fusion protein.
7:
- A polypeptide consisting of a partial sequence of a polypeptide having the amino acid sequence as shown in SEQ ID NO:
- 2, wherein the N-terminus of the partial sequence starts between positions 564 and 621 of SEQ ID NO:
- 2.
8:
- The polypeptide according to claim 7, wherein the polypeptide has the following activity (a) or (b):
- (a) promoting spine formation;
- or
- (b) activating Rac.
1 more element
9:
- A polypeptide consisting of a partial sequence of a polypeptide consisting of the amino acid sequence as shown in SEQ ID NO:
- 2, wherein the former polypeptide has the following amino acid sequence (a) or (b) and yet has the following activity (c) or (d):
- (a) an amino acid sequence having at least 95% or more homology to a partial amino acid sequence of SEQ ID NO:
- 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO:
- 2;
- or
- (b) an amino acid sequence encoded by a polynucleotide which hybridizes to the complementary strand of a polynucleotide encoding a partial amino acid sequence of SEQ ID-NO:
- 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO:
- 2 under stringent conditions;
- (c) promoting spine formation;
- or
- (d) activating Rac.
9 more elements
10:
- A polypeptide selected from the following (a) and (b):
- (a) a polypeptide consisting of the amino acid sequence as shown in SEQ ID NO:
- 2n where n represents an integer from 45 to 83;
- (b) a polypeptide which has at least 80% or more homology to a polypeptide consisting of the amino acid sequence as shown in SEQ ID NO:
- 2n where n represents an integer from 45 to 83 and yet has the following activity (c) or (d):
- (c) promoting spine formation;
- or
- (d) activating Rac.
5 more elements
11:
- A polypeptide having the amino acid sequence as shown in SEQ ID NO:
- 90, 92 or 196.
12:
- A polypeptide according to any one of claims 7, 9, or 10, wherein the polypeptide has an amino acid sequence of a fusion protein.
13:
- An antibody to the polypeptide according to any one of claims 7, 9 to 12.
14:
- A kit containing the polynucleotide according to any one of claims 1, 3, 4 to 6 and the antibody according to claim 13.
15:
- A kit containing the polypeptide according to any one of claims 7, 9 to 12 and the antibody according to claim 13.
16:
- A method of screening for compounds which affect the processing of EphA4 by γ-secretase, comprising the following steps:
- (i) contacting a first biological composition containing γ-secretase or a biologically active fragment thereof with a second biological composition containing EphA4 in the presence and absence of a candidate compound;
- (ii) measuring the number of spines in spine forming cells in the presence and absence of the candidate compound;
- (iii) selecting those candidate compounds which affect the number of spines based on the number of spines measured in step (ii);
- and
- (iv) identifying the candidate compounds selected in step (iii) as compounds which affect the processing of EphA4 by γ-secretase.
3 more elements
17:
- The method according to claim 16, comprising identifying a candidate compound as a compound which activates the processing of EphA4 through γ-secretase when the number of spines in the presence of said candidate compound was increased relative to the number of spines in the absence of said candidate compound in the measurement of spines in step (ii).
18:
- The method according to claim 16, comprising identifying a candidate compound as a compound which inhibits the processing of EphA4 through γ-secretase when the number of spines in the presence of said candidate compound was decreased relative to the number of spines in the absence of said candidate compound in the measurement of spines in step (ii).
19:
- A method of screening for compounds which affect spine formation by γ-secretase-processed EphA4, comprising the following steps:
- (i) culturing spine forming cells which have expressed intracellular EphA4 cleaved by γ-secretase;
- (ii) measuring the number of spines in the spine forming cells cultured in step (i) in the presence and absence of a candidate compound;
- (iii) selecting those candidate compounds which affect the number of spines based on the number of spines measured in step (ii);
- and
- (iv) identifying the candidate compounds selected in step (iii) as compounds which affect spine formation by γ-secretase-processed EphA4.
3 more elements
20:
- The method according to claim 19, comprising evaluating a candidate compound as a compound which activates spine formation through γ-secretase-cleaved EphA4 when the number of spines after the expression of γ-secretase-cleaved EphA4 was increased relative to the number of spines before the expression of γ-secretase-cleaved EphA4 in the measurement of spines in step (ii).
21:
- The method according to claim 19, comprising evaluating a candidate compound as a compound which inhibits spine formation through EphA4 when the number of spines after the expression of γ-secretase-cleaved EphA4 was decreased relative to the number of spines before the expression of γ-secretase-cleaved EphA4 in the measurement of spines in step (ii).
22:
- A method of screening for compounds which affect spine formation by γ-secretase-processed EphA4, comprising the following steps:
- (i) culturing Rae expressing cells which have expressed intracellular EphA4 cleaved by γ-secretase;
- (ii) measuring Rae activity in the Rae expressing cells cultured in step (i) in the presence and absence of a candidate compound;
- (iii) selecting those candidate compounds which affect Rac activity based on the measuring in step (ii);
- and
- (iv) identifying the candidate compounds selected in step (iii) as compounds which affect spine formation by γ-secretase-processed EphA4.
3 more elements
23:
- The method according to claim 22, comprising evaluating a candidate compound as a compound which activates spine formation through γ-secretase-cleaved EphA4 when the Rac activity in the presence of said candidate compound was increased relative to the Rac activity in the absence of said candidate compound in the measurement of Rac activity in step (ii).
24:
- The method according to claim 22, comprising evaluating a candidate compound as a compound which inhibits spine formation through EphA4 when the Rac activity in the presence of said candidate compound was decreased relative to the Rac activity in the absence of said candidate compound in the measurement of Rac activity in step (ii).
25:
- A method of screening for compounds which affect Rac activity mediated by γ-secretase-processed EphA4, comprising the following steps:
- (i) culturing Rac expressing cells which have expressed intracellular EphA4 cleaved by γ-secretase;
- (ii) measuring Rac activity in the Rac expressing cells cultured in step (i) in the presence and absence of a candidate compound;
- (iii) selecting those candidate compounds which affect Rac activity based on the measuring in step (ii);
- and
- (iv) identifying the candidate compounds selected in step (iii) as compounds which affect Rac activity mediated by γ-secretase-processed EphA4.
3 more elements
26:
- The method according to claim 25, comprising evaluating a candidate compound as a compound which activates Rac through γ-secretase-cleaved EphA4 when the Rac activity in the presence of said candidate compound was increased relative to the Rac activity in the absence of said candidate compound in the measurement of Rae activity in step (ii).
27:
- The method according to claim 25, comprising evaluating a candidate compound as a compound which inhibits Rac activity through EphA4 when the Rae activity in the presence of said candidate compound was decreased relative to the Rae activity in the absence of said candidate compound in the measurement of Rae activity in step (ii).